ES2255325T3 - Vacunas mejoradas. - Google Patents
Vacunas mejoradas.Info
- Publication number
- ES2255325T3 ES2255325T3 ES99963705T ES99963705T ES2255325T3 ES 2255325 T3 ES2255325 T3 ES 2255325T3 ES 99963705 T ES99963705 T ES 99963705T ES 99963705 T ES99963705 T ES 99963705T ES 2255325 T3 ES2255325 T3 ES 2255325T3
- Authority
- ES
- Spain
- Prior art keywords
- ige
- mammal
- immunogenic
- polypeptide
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960005486 vaccine Drugs 0.000 title claims description 48
- 230000001976 improved effect Effects 0.000 title description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 226
- 229920001184 polypeptide Polymers 0.000 claims abstract description 224
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 224
- 230000002163 immunogen Effects 0.000 claims abstract description 113
- 241000124008 Mammalia Species 0.000 claims abstract description 63
- 230000004044 response Effects 0.000 claims abstract description 57
- 150000001413 amino acids Chemical class 0.000 claims abstract description 31
- 241000289695 Eutheria Species 0.000 claims abstract description 10
- 241000894007 species Species 0.000 claims abstract description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 64
- 108020004707 nucleic acids Proteins 0.000 claims description 48
- 102000039446 nucleic acids Human genes 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 40
- 241000282414 Homo sapiens Species 0.000 claims description 30
- 210000004027 cell Anatomy 0.000 claims description 28
- 229920002704 polyhistidine Polymers 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 239000000539 dimer Substances 0.000 claims description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 7
- 241000289371 Ornithorhynchus anatinus Species 0.000 claims description 5
- 230000004048 modification Effects 0.000 claims description 5
- 238000012986 modification Methods 0.000 claims description 5
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 241000289619 Macropodidae Species 0.000 claims description 3
- 241000289581 Macropus sp. Species 0.000 claims description 3
- 241001520299 Phascolarctos cinereus Species 0.000 claims description 3
- 241000289674 Vombatidae Species 0.000 claims description 3
- 230000028327 secretion Effects 0.000 claims description 3
- 230000001323 posttranslational effect Effects 0.000 claims description 2
- 230000003169 placental effect Effects 0.000 claims 4
- 241000700159 Rattus Species 0.000 description 99
- 230000000694 effects Effects 0.000 description 34
- 102000004127 Cytokines Human genes 0.000 description 29
- 108090000695 Cytokines Proteins 0.000 description 29
- 241000289427 Didelphidae Species 0.000 description 21
- 239000000463 material Substances 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 14
- 230000028993 immune response Effects 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 206010020751 Hypersensitivity Diseases 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 108010058846 Ovalbumin Proteins 0.000 description 10
- 229940092253 ovalbumin Drugs 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 9
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 102000009438 IgE Receptors Human genes 0.000 description 7
- 108010073816 IgE Receptors Proteins 0.000 description 7
- 230000007815 allergy Effects 0.000 description 7
- 238000002255 vaccination Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 239000007928 intraperitoneal injection Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 241000282898 Sus scrofa Species 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 5
- 239000010931 gold Substances 0.000 description 5
- 229910052737 gold Inorganic materials 0.000 description 5
- 210000003630 histaminocyte Anatomy 0.000 description 5
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 241000700157 Rattus norvegicus Species 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000006992 Interferon-alpha Human genes 0.000 description 3
- 108010047761 Interferon-alpha Proteins 0.000 description 3
- 241000532838 Platypus Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 210000004897 n-terminal region Anatomy 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 241000380131 Ammophila arenaria Species 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 101150059079 EBNA1 gene Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 101710136524 X polypeptide Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003912 basophilic leucocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000011685 brown norway rat Methods 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 241001125840 Coryphaenidae Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000282520 Papio Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101001044455 Rattus norvegicus Interferon gamma Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 for example Substances 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229960001539 poliomyelitis vaccine Drugs 0.000 description 1
- 208000025223 poliovirus infection Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000009959 type I hypersensitivity Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10665298P | 1998-11-02 | 1998-11-02 | |
| US106652P | 1998-11-02 | ||
| US401636 | 1999-09-22 | ||
| US09/401,636 US6913749B2 (en) | 1998-11-02 | 1999-09-22 | Immunogenic polypeptides for inducing anti-self IgE responses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2255325T3 true ES2255325T3 (es) | 2006-06-16 |
Family
ID=26803871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99963705T Expired - Lifetime ES2255325T3 (es) | 1998-11-02 | 1999-10-21 | Vacunas mejoradas. |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US6913749B2 (enExample) |
| EP (1) | EP1135158B1 (enExample) |
| JP (2) | JP4205861B2 (enExample) |
| KR (1) | KR100559918B1 (enExample) |
| AT (1) | ATE314087T1 (enExample) |
| AU (1) | AU771889B2 (enExample) |
| CA (1) | CA2348756A1 (enExample) |
| DE (1) | DE69929240T2 (enExample) |
| DK (1) | DK1135158T3 (enExample) |
| ES (1) | ES2255325T3 (enExample) |
| HU (1) | HUP0105392A3 (enExample) |
| IL (1) | IL142582A0 (enExample) |
| NO (1) | NO20012135L (enExample) |
| NZ (1) | NZ511079A (enExample) |
| PL (1) | PL348611A1 (enExample) |
| PT (1) | PT1135158E (enExample) |
| WO (1) | WO2000025722A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7658101A (en) * | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| EP2361635A3 (en) * | 2000-08-30 | 2011-09-14 | Pfizer Products Inc. | Anti IgE vaccines |
| JP2004508028A (ja) * | 2000-09-06 | 2004-03-18 | ファーメクサ エイ／エス | ＩｇＥをダウン−レギュレートさせる方法 |
| CA2698079C (en) | 2001-02-20 | 2015-01-13 | Ortho-Mcneil Pharmaceutical, Inc. | A cell therapy method for the treatment of tumors |
| US20040071671A1 (en) | 2001-02-20 | 2004-04-15 | Leturcq Didier J. | Cell therapy method for the treatment of tumors |
| ES2329453T3 (es) * | 2001-05-15 | 2009-11-26 | Ortho Mcneil Janssen Pharm | Cebado ex-vivo para generar linfocitos t citotoxicos especificos del ligando cd40 para tratar enfermedades autoinmunitarias y alergicas. |
| JP2003047482A (ja) * | 2001-05-22 | 2003-02-18 | Pfizer Prod Inc | 非アナフィラキシー誘発性ＩｇＥワクチン |
| CA2486464A1 (en) * | 2002-05-21 | 2003-11-27 | Resistentia Pharmaceuticals Ab | Chimeric ige polypeptides and host cells |
| CA2497660A1 (en) * | 2002-09-05 | 2004-03-18 | Resistentia Pharmaceuticals Ab | Allergy vaccines |
| US20080118524A1 (en) * | 2006-10-20 | 2008-05-22 | Stefan Persson | Anti-IgE Vaccines |
| US20100166804A1 (en) * | 2007-05-23 | 2010-07-01 | Dennis Penn | Methods |
| WO2009142772A2 (en) * | 2008-05-23 | 2009-11-26 | Mastcell Pharmaceuticals, Inc. | Methods and treatment for allergies and inflammation associated with gastrointestinal diseases |
| WO2010067286A2 (en) | 2008-12-09 | 2010-06-17 | Pfizer Vaccines Llc | IgE CH3 PEPTIDE VACCINE |
| EP2942061A3 (en) | 2010-06-07 | 2016-01-13 | Pfizer Vaccines LLC | Ige ch3 peptide vaccine |
| US9187553B2 (en) * | 2012-01-25 | 2015-11-17 | Swey-Shen Chen | Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold |
| WO2013156054A1 (en) | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| EP2862873B1 (en) | 2012-06-18 | 2020-04-29 | Nippon Zenyaku Kogyo Co., Ltd. | IgE PEPTIDE VACCINE |
| SG11201806427WA (en) | 2016-02-16 | 2018-08-30 | Regeneron Pharma | Non-human animals having a mutant kynureninase gene |
| EP4582442A3 (en) | 2019-06-24 | 2025-10-29 | Universität Stuttgart | Tnfr2 agonists with improved stability |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4767842A (en) | 1973-05-07 | 1988-08-30 | The Ohio State University | Antigenic modification of polypeptides |
| US5698201A (en) | 1973-05-07 | 1997-12-16 | The Ohio State University | Method for treatment of antigenically modified polypeptides |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4483793A (en) | 1982-10-04 | 1984-11-20 | The Regents Of The University Of California | Dimeric oligopeptides as heptenic epitopic sites for hepatitis |
| US4782137A (en) | 1984-01-24 | 1988-11-01 | Immunex Corporation | Synthesis of protein with an identification peptide, and hybrid polypeptide incorporating same |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
| GB8727045D0 (en) | 1987-11-19 | 1987-12-23 | Research Corp Ltd | Immunoglobulin e competitor |
| US5254671A (en) * | 1990-04-27 | 1993-10-19 | Tanox Biosystems, Inc. | Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor |
| DE122006000007I2 (de) | 1987-12-31 | 2008-03-27 | Tanox Inc | -tragenden b-lymphocyten befinden. |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| GB8910263D0 (en) | 1989-05-04 | 1989-06-21 | Ciba Geigy Ag | Monoclonal antibodies specific for an immunoglobulin isotype |
| GB8913737D0 (en) | 1989-06-15 | 1989-08-02 | Univ Birmingham | A novel anti-allergy treatment |
| US5955076A (en) | 1989-06-15 | 1999-09-21 | Peptide Therapeutics Limited | Immunoactive peptides and antibodies and their use in anti-allergy treatment |
| AU651949B2 (en) | 1989-07-14 | 1994-08-11 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| US5733553A (en) | 1989-09-29 | 1998-03-31 | Talwar; Gursaran Prasad | Recombinant birth control vaccine |
| AU645783B2 (en) | 1990-01-23 | 1994-01-27 | Tanox Biosystems, Inc. | Extracellular segments of human epsilon immunoglobulin anchoring peptides and antibodies specific therefor |
| EP0605410B1 (en) | 1990-05-25 | 1995-08-16 | Peptide Therapeutics Limited | Immunodiagnostic assay for rheumatoid arthritis |
| US5196197A (en) | 1990-08-29 | 1993-03-23 | National Institute Of Immunology | Reversible fertility control for prevention of pregnancy in females |
| FI932477L (fi) * | 1990-12-13 | 1993-06-11 | Immunex Corp | Receptorer foer leukemi-inhiberande faktor |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| US5837686A (en) | 1991-11-25 | 1998-11-17 | Peptide Therapeutics Limited | Peptides and antibodies for treatment of rheumatoid arthritis |
| EP0662085A1 (en) | 1992-09-01 | 1995-07-12 | International Centre for Genetic Engineering and Biotechnology | Peptide showing cross-reactivity with the anti-hepatitis b surface antigen antiserum |
| WO1994008601A1 (en) | 1992-10-14 | 1994-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of b cell lymphoma tumor resistance using idiotype/cytokine conjugates |
| US5762931A (en) | 1992-12-31 | 1998-06-09 | National Institute Of Immunology | Anti-cancer utility of HCG vaccines |
| US5532142A (en) * | 1993-02-12 | 1996-07-02 | Board Of Regents, The University Of Texas System | Method of isolation and purification of fusion polypeptides |
| US5552537A (en) * | 1993-03-24 | 1996-09-03 | The Regents Of The University Of California | IgE isoforms and methods of use |
| US5501855A (en) | 1993-09-02 | 1996-03-26 | Talwar; Gursaran P. | Neem oil as a male contraceptive |
| DK96493D0 (da) * | 1993-08-26 | 1993-08-26 | Mouritsen Og Elsner Aps | Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden |
| US5874085A (en) | 1993-11-10 | 1999-02-23 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Vaccine for enhanced production of IgA antibodies |
| FR2715304B1 (fr) | 1994-01-26 | 1996-04-26 | Merieux Serums Vaccins Pasteur | Vaccin anti-allergique. |
| CN1146772A (zh) | 1994-03-28 | 1997-04-02 | 美国联合生物医学公司 | 用于治疗过敏反应的合成肽免疫原 |
| US5651981A (en) * | 1994-03-29 | 1997-07-29 | Northwestern University | Cationic phospholipids for transfection |
| CA2203165A1 (en) | 1994-10-25 | 1996-05-02 | United Biomedical, Inc. | Synthetic ige membrane anchor peptide immunogens for the treatment of allergy |
| GB9422294D0 (en) | 1994-11-04 | 1994-12-21 | Peptide Therapeutics Ltd | Peptides for anti-allergy treatment |
| US6949244B1 (en) | 1995-12-20 | 2005-09-27 | The Board Of Trustees Of The University Of Kentucky | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof |
| JPH08333390A (ja) | 1995-04-07 | 1996-12-17 | Hoechst Japan Ltd | ペプチド及びそれからなる自己免疫疾患治療剤 |
| AU716716B2 (en) | 1995-07-17 | 2000-03-02 | Medivir Uk Ltd | Cysteine protease inhibitors for use in treatment of IgE mediated allergic diseases |
| ZA966075B (en) | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| AU719609B2 (en) | 1996-03-01 | 2000-05-11 | Novartis Ag | Peptide immunogens for vaccination against and treatment of allergy |
| CA2262001C (en) | 1996-08-05 | 2003-05-20 | President And Fellows Of Harvard College | Mhc binding peptide oligomers and methods of use |
| ZA983148B (en) | 1997-04-15 | 1999-10-15 | Ferring Farma Lab | Modified TNFÓ, DNA encoding such modified TNFÓ and vacines comprising said TNFÓ and DNA. |
| US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| EP1279401B1 (en) | 1997-09-05 | 2008-01-09 | GlaxoSmithKline Biologicals S.A. | Oil in water emulsions containing saponins |
| AU2674299A (en) | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Targeting of genetic vaccine vectors |
| US6299875B1 (en) | 1998-06-04 | 2001-10-09 | Panacea Pharmaceuticals, Llc | Methods to block IGE binding to cell surface receptors of mast cells |
| TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
| DE69918146T2 (de) | 1998-10-05 | 2005-07-07 | Pharmexa A/S | Verfahren zur therapeutischen impfung |
| DE69939836D1 (de) | 1998-11-30 | 2008-12-11 | Cytos Biotechnology Ag | Molekulare anordnung von allergenen, verfahren zur deren herstellung und deren verwendung |
| GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
| EA200101125A1 (ru) | 1999-04-23 | 2002-04-25 | Фармекса А/С | Способ понижающей регуляции активности il5 |
| AU7658101A (en) | 2000-07-28 | 2002-02-13 | Cytos Biotechnology Ag | Compositions for inducing self-specific anti-ige antibodies and uses thereof |
| JP2004508028A (ja) | 2000-09-06 | 2004-03-18 | ファーメクサ エイ／エス | ＩｇＥをダウン−レギュレートさせる方法 |
| US20040198961A1 (en) | 2001-06-15 | 2004-10-07 | Ling-Ling An | Fce fusion proteins for treatment of allergy and asthma |
-
1999
- 1999-09-22 US US09/401,636 patent/US6913749B2/en not_active Expired - Fee Related
- 1999-10-21 WO PCT/SE1999/001896 patent/WO2000025722A2/en not_active Ceased
- 1999-10-21 AU AU20081/00A patent/AU771889B2/en not_active Ceased
- 1999-10-21 DE DE69929240T patent/DE69929240T2/de not_active Expired - Lifetime
- 1999-10-21 PT PT99963705T patent/PT1135158E/pt unknown
- 1999-10-21 KR KR1020017005276A patent/KR100559918B1/ko not_active Expired - Fee Related
- 1999-10-21 AT AT99963705T patent/ATE314087T1/de not_active IP Right Cessation
- 1999-10-21 EP EP99963705A patent/EP1135158B1/en not_active Expired - Lifetime
- 1999-10-21 HU HU0105392A patent/HUP0105392A3/hu not_active Application Discontinuation
- 1999-10-21 ES ES99963705T patent/ES2255325T3/es not_active Expired - Lifetime
- 1999-10-21 DK DK99963705T patent/DK1135158T3/da active
- 1999-10-21 PL PL99348611A patent/PL348611A1/xx not_active Application Discontinuation
- 1999-10-21 IL IL14258299A patent/IL142582A0/xx not_active IP Right Cessation
- 1999-10-21 CA CA002348756A patent/CA2348756A1/en not_active Abandoned
- 1999-10-21 NZ NZ511079A patent/NZ511079A/en not_active IP Right Cessation
- 1999-10-21 JP JP2000579167A patent/JP4205861B2/ja not_active Expired - Fee Related
-
2001
- 2001-04-30 NO NO20012135A patent/NO20012135L/no unknown
-
2002
- 2002-06-19 US US10/176,664 patent/US7459158B2/en not_active Expired - Fee Related
-
2003
- 2003-09-29 US US10/673,594 patent/US20040076625A1/en not_active Abandoned
-
2005
- 2005-09-07 JP JP2005258648A patent/JP4188353B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002531064A (ja) | 2002-09-24 |
| JP4188353B2 (ja) | 2008-11-26 |
| ATE314087T1 (de) | 2006-01-15 |
| US7459158B2 (en) | 2008-12-02 |
| JP4205861B2 (ja) | 2009-01-07 |
| IL142582A0 (en) | 2002-03-10 |
| HUP0105392A2 (hu) | 2002-04-29 |
| DE69929240D1 (de) | 2006-02-02 |
| DE69929240T2 (de) | 2006-08-31 |
| KR100559918B1 (ko) | 2006-03-13 |
| HUP0105392A3 (en) | 2008-04-28 |
| PL348611A1 (en) | 2002-06-03 |
| AU2008100A (en) | 2000-05-22 |
| KR20010089364A (ko) | 2001-10-06 |
| NZ511079A (en) | 2003-08-29 |
| WO2000025722A2 (en) | 2000-05-11 |
| US20030031663A1 (en) | 2003-02-13 |
| EP1135158B1 (en) | 2005-12-28 |
| HK1042844A1 (en) | 2002-08-30 |
| WO2000025722A3 (en) | 2000-10-12 |
| NO20012135D0 (no) | 2001-04-30 |
| US6913749B2 (en) | 2005-07-05 |
| CA2348756A1 (en) | 2000-05-11 |
| PT1135158E (pt) | 2006-05-31 |
| DK1135158T3 (da) | 2006-05-15 |
| EP1135158A2 (en) | 2001-09-26 |
| NO20012135L (no) | 2001-06-25 |
| US20010038843A1 (en) | 2001-11-08 |
| AU771889B2 (en) | 2004-04-08 |
| US20040076625A1 (en) | 2004-04-22 |
| JP2006068015A (ja) | 2006-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2255325T3 (es) | Vacunas mejoradas. | |
| ES2144424T5 (es) | Vacuna que comprende parte de la region constante de ige para el tratamiento de reacciones alergicas inducidas por ige. | |
| ES2312569T3 (es) | Anticuerpos humanizados. | |
| ES2186796T5 (es) | Procedimientos para el tratamiento del asma alergica. | |
| ES2962794T3 (es) | Cisteina proteasa | |
| ES2221717T3 (es) | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. | |
| KR100308444B1 (ko) | 이종 t-세포 에피토우프를 사용하여 자가 단백질에 대해항체반응을유도하는방법 | |
| ES2550099T3 (es) | Antagonistas del receptor Nogo | |
| ES2362386T3 (es) | Proteínas activas biológicas que tienen estabilidad aumentada in vivo y/o in vitro. | |
| BR112019026803A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
| BR112019026907A2 (pt) | Anticorpos apenas de cadeia pesadaanti-bcma, polinucleotídeo, vetor, célula,composição farmacêutica, seus usos e método paraproduzir os mesmos | |
| JPH04504424A (ja) | 膜結合ＩｇＡに存在するが分泌ＩｇＡに存在しない抗原エピトープ | |
| ES2427147T3 (es) | Anticuerpo sHlgM12 útil para tratar esclerosis múltiple | |
| BRPI0609100A2 (pt) | conjugado para alvejamento de fármaco, método de produzir o referido conjugado, bem como composição contendo o mesmo | |
| CN108602857A (zh) | 重组IgG Fc多聚体 | |
| ES2438444T3 (es) | Variantes de la familia de IL-1 | |
| ES2806205T3 (es) | Cadena alfa del receptor de IgE de alta afinidad de fusión Fc | |
| BR112020012554A2 (pt) | anticorpos de cadeia pesada que se ligam a cd22 | |
| RU2678810C2 (ru) | ХИМЕРНЫЙ БЕЛОК, СОСТАВЛЕННЫЙ ИЗ ДОМЕНА АНТАГОНИСТА NGF И ДОМЕНА АНТАГОНИСТА TNFα | |
| US20100021486A1 (en) | Tslp vaccine for the treatment of th2 mediated inflammatory conditions | |
| RU2214279C2 (ru) | Усовершенствованные вакцины | |
| ES2316780T3 (es) | Vacunas contra alergia. | |
| WO2008066443A1 (en) | Il-33 vaccine for the treatment of inflammatory conditions with a strong th2 component | |
| EP1621209A2 (en) | Vaccines based on domains of chimeric immunoglobulin E peptides | |
| HK1042844B (en) | Enhanced vaccines based on chimeric immunoglobulin e peptides |